Literature DB >> 11512564

Concentration of nitric oxide (NO) in spinal fluid of chronic spinal disease.

Y Yumite1, K Takeuchi, Y Harada, N Ogawa, H Inoue.   

Abstract

We studied total nitric oxide (nitrite + nitrate) (NO) levels in cerebrospinal fluid (CSF) of chronic spinal diseases in nonsmokers (133 patients: 76 men and 57 women; mean age, 63 years; range, 15-92 years) by the Griess method to clarify the role of NO in different spinal diseases. The extent of compression in terms of numbers of disc level at the compressed spinal nerve and neurological evaluation were also assessed according to the Japanese Orthopaedic Association scores. The spinal diseases included cervical myelopathy and radiculopathy (cervical disease group), ossification of yellow ligament (thoracic disease group), and lumbar disc herniation, lumbar canal stenosis and lumbar spondylolisthesis (lumbar disease group). NO levels in the spinal disease groups (4.98+/-2.28 micromol/l: mean +/- SD) were significantly higher than that in the control group (2.53+/-0.94 micromol/l). An inverse correlation was detected between the elevated levels of NO and the grade of clinical symptoms in the cervical disorders. The number of disc level at the compressed spinal nerve was positively correlated with elevated NO levels in CSF in the cervical and lumbar disorder groups. These results indicate that nerve compression may elevate NO levels in CSF, and that NO concentration in the CSF might be a useful marker of damage to nervous system in spinal disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11512564     DOI: 10.18926/AMO/31996

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  1 in total

1.  Clinical significance of cerebrospinal fluid nitric oxide concentrations in degenerative cervical and lumbar diseases.

Authors:  Hiroshi Denda; Shinji Kimura; Akiyoshi Yamazaki; Noboru Hosaka; Yuichi Takano; Kenji Imura; Yoichi Yajiri; Naoto Endo
Journal:  Eur Spine J       Date:  2010-12-29       Impact factor: 3.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.